Robbins LLP Reminds TMCI Stockholders With Large Losses to Contact the Firm for Information About the Class Action Against Treace Medical Concepts, Inc.

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand and utilization of its primary product [2] - As a result of these undisclosed factors, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Treace Medical and must file their papers by June 10, 2025, to serve as lead plaintiff [3] - Shareholders can choose to remain absent class members without participating in the case and still be eligible for recovery [3] Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]